Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
JAMA Network Open
|
April 28, 2021
Informed Consent-We Can and Should Do Better
Stefan C Grant
JAMA
|
May 22, 2014
Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design
Boris Pasche, Stefan C Grant
Cancer Chemotherapy and Pharmacology
|
August 17, 2004
Phase I study of green tea extract in patients with advanced lung cancer
Scott A Laurie, Vincent A Miller, Stefan C Grant, et al.
Oncotarget
|
October 6, 2016
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment
Cara C Schafer, Yong Wang, Kenneth P Hough, et al.
Molecular Cancer
|
April 14, 2018
Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
Liang Liu, Jimmy Ruiz, Stacey S O'Neill, et al.
Clinical Lung Cancer
|
January 10, 2020
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice
Laurie E Steffen McLouth, Thomas W Lycan, Beverly J Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2005
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
Giuseppe Giaccone, Channa Debruyne, Enriqueta Felip, et al.
Cancer Chemotherapy and Pharmacology
|
September 24, 2015
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)
Daniel J Allendorf, Rodolfo E Bordoni, Stefan C Grant, et al.
Cancer Research
|
October 3, 2013
Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways
Anandi Sawant, Cara C Schafer, Tong Huan Jin, et al.
JCO Oncology Practice
|
February 4, 2021
Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice
Laurie E McLouth, Chandylen L Nightingale, Beverly J Levine, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
JAMA Network Open
|
April 28, 2021
Informed Consent-We Can and Should Do Better
Stefan C Grant
JAMA
|
May 22, 2014
Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design
Boris Pasche, Stefan C Grant
Cancer Chemotherapy and Pharmacology
|
August 17, 2004
Phase I study of green tea extract in patients with advanced lung cancer
Scott A Laurie, Vincent A Miller, Stefan C Grant, et al.
Oncotarget
|
October 6, 2016
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment
Cara C Schafer, Yong Wang, Kenneth P Hough, et al.
Molecular Cancer
|
April 14, 2018
Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
Liang Liu, Jimmy Ruiz, Stacey S O'Neill, et al.
Clinical Lung Cancer
|
January 10, 2020
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice
Laurie E Steffen McLouth, Thomas W Lycan, Beverly J Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2005
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
Giuseppe Giaccone, Channa Debruyne, Enriqueta Felip, et al.
Cancer Chemotherapy and Pharmacology
|
September 24, 2015
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)
Daniel J Allendorf, Rodolfo E Bordoni, Stefan C Grant, et al.
Cancer Research
|
October 3, 2013
Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways
Anandi Sawant, Cara C Schafer, Tong Huan Jin, et al.
JCO Oncology Practice
|
February 4, 2021
Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice
Laurie E McLouth, Chandylen L Nightingale, Beverly J Levine, et al.
Page
of 2